These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 6349467)

  • 21. Initial human trials with an investigational new drug (phase I and 2): planning an management.
    Vaidya AB; Vaidya RA
    J Postgrad Med; 1981 Oct; 27(4):197-213. PubMed ID: 7338825
    [No Abstract]   [Full Text] [Related]  

  • 22. A technique for the comparison of biological distribution and solvent partition of drugs.
    Gigon PL; van Hees H; Bickel MH
    Experientia; 1983 Jul; 39(7):801-4. PubMed ID: 6861976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Animal model and drug activity (proceedings)].
    Rico AG
    Ann Biol Clin (Paris); 1978; 36(3):214-7. PubMed ID: 101102
    [No Abstract]   [Full Text] [Related]  

  • 24. Modeling promiscuity based on in vitro safety pharmacology profiling data.
    Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
    ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioavailability of drugs: principles and problems. Report of a WHO Scientific Group.
    World Health Organ Tech Rep Ser; 1973 Nov; 536():1-17. PubMed ID: 4204708
    [No Abstract]   [Full Text] [Related]  

  • 26. Animal data in perspective.
    Uehleke H
    Int J Clin Pharmacol; 1973 Nov; 8(3):239-43. PubMed ID: 4772084
    [No Abstract]   [Full Text] [Related]  

  • 27. The significance of properly designed pre-clinical studies in the clinical evaluation of new drugs.
    Garrett ER
    Int Z Klin Pharmakol Ther Toxikol; 1970 Dec; 4(1):6-20. PubMed ID: 4924331
    [No Abstract]   [Full Text] [Related]  

  • 28. How do the top 12 pharmaceutical companies operate safety pharmacology?
    Ewart L; Gallacher DJ; Gintant G; Guillon JM; Leishman D; Levesque P; McMahon N; Mylecraine L; Sanders M; Suter W; Wallis R; Valentin JP
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):66-70. PubMed ID: 22510338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological methods in toxicology: general concepts.
    Zbinden G
    Pharmacol Ther B; 1979; 5(1-3):3-6. PubMed ID: 386372
    [No Abstract]   [Full Text] [Related]  

  • 30. [Methodological characteristics of the preclinical study of the safety of drug preparations for children].
    Mal'tseva LF; Muratova GP; Motovilova VG; Sirinova NA
    Farmakol Toksikol; 1988; 51(4):96-100. PubMed ID: 3191987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety evaluation to support First-In-Man investigations I: kinetic and safety pharmacology studies.
    Baldrick P
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):230-6. PubMed ID: 18501489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Control, drug preparation and dosage in the designing of experiments (author's transl)].
    Chen X
    Zhonghua Yi Xue Za Zhi; 1981 Jun; 61(6):335-8. PubMed ID: 6796231
    [No Abstract]   [Full Text] [Related]  

  • 33. Annual review of pharmacology and toxicology: review of reviews.
    Leake CD
    Annu Rev Pharmacol Toxicol; 1978; 18():581-8. PubMed ID: 348070
    [No Abstract]   [Full Text] [Related]  

  • 34. Perspectives in the field of drug metabolism.
    Garattini S
    Drug Metab Rev; 1994; 26(3):537-73. PubMed ID: 7924903
    [No Abstract]   [Full Text] [Related]  

  • 35. Image processing and analysis in drug discovery and clinical trials.
    Sonka M; Grunkin M
    IEEE Trans Med Imaging; 2002 Oct; 21(10):1209-11. PubMed ID: 12585702
    [No Abstract]   [Full Text] [Related]  

  • 36. Chemical complementation: a definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets.
    Vogt A; Lazo JS
    Pharmacol Ther; 2005 Aug; 107(2):212-21. PubMed ID: 15925410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for dealing with metabolite elucidation in drug discovery and development.
    Nassar AE; Talaat RE
    Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of reviews.
    Leake CD
    Annu Rev Pharmacol; 1973; 13():455-63. PubMed ID: 4354665
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety pharmacology methods and models in an evolving regulatory environment.
    Pugsley MK; de Korte T; Authier S; Huang H; Accardi MV; Curtis MJ
    J Pharmacol Toxicol Methods; 2017 Sep; 87():1-6. PubMed ID: 28461240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.